Roche\'s Tecentriq scores CHMP recommendation in PDL1 metastatic triplenegative breast cancer

Roche's Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer

Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination with Abraxane chemotherapy to be used in the initial treatment of PD-L1-positive, metastatic triple-negative breast cancer in adult patients who have not previously received chemotherapy, it has emerged.

While not binding, the positive ruling is expected to be a good predictor of a final regulatory decision for the therapy in Europe.

read more

More From BioPortfolio on "Roche's Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer"